Figure 2From: Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolismAnti-Factor Xa activity after administration of oral rivaroxaban and subcutaneous enoxaparin alone and in combination. Rivaroxaban 10Â mg, enoxaparin 40Â mg. Median values in healthy subjects. Reproduced with permission from Kubitza D et al. [35].Back to article page